All news
FAPA On It’s 30th Anniversary
17 March 2023The day was filled with informative talks, including an introduction from Prof. Dr Eric Van Cutsem for the Dutch-speaking audience of patients, out...
Imfinzi & Imjudo Immunotherapy Drug Combinations Approved in the EU for the Treatment of Advanced Liver Cancer
2 March 2023The combination of durvalumab (Imfinzi) and tremelimumab (Imjudo) immunotherapies has been approved by the European Commission (EC) for the first-l...
Zolbetuximab Plus Chemotherapy Extends Overall Survival for Patients with Advanced or Metastatic Gastric & Gastro-oesophageal Junction Adenocarcinoma
16 February 2023The Annual American Society of Clinical Oncologists Gastrointestinal Cancers Symposium (ASCO GI) kicked off the year with lots of new data in the f...
Member Update from Turkey
16 February 2023The devastating earthquakes that struck southern Türkiye and northern Syria on 6 February have destroyed homes, hospitals, and roads.
...
How Is Your Country Doing? Launch of European Country Cancer Profiles
16 February 2023Together with nearly 200 participants, DiCE joined the online launch of Country Cancer Profiles on the European Cancer Inequalities Registry. The ...
European Commission Gathered Evidence on Vaccine-preventable Cancers
16 February 2023Earlier this month, DiCE responded to the call for evidence by the EU Commission. DiCE highlighted that to mitigate the rising incidence of Liver ...
DiCE Supports Act4Biosimilars to Increase Patient Access to Biologic Medicines
16 February 2023On 30 January, the Act4Biosimilars initiative hosted a virtual meeting with key stakeholders from across the healthcare space to discuss the Action...
16 February is World Cholangiocarcinoma Day
13 February 2023DiCE is proud to support GCCA’s international effort to raise much-needed awareness of CCA, devastating cancer that occurs in the bile ducts in o...
Interventions to Reduce Cancer Screening Inequities
1 February 2023A group of patients and patient advocacy organisations published a promising multistep strategy to reduce cancer screening inequalities In Internat...
First Immunotherapy Drug Durvalumab Plus Chemotherapy Approved in Europe for Advanced Biliary Cancer
11 January 2023On 21 December the European Commission (EC) approved the use of durvalumab (Imfinzi ®) plus chemotherapy (gemcitabine plus cisplatin) as the first...